Allogeneic hematopoietic stem cell transplant (allo-HSCT) may be a successful curative treatment for T-cell patients with poor survival and/or limited treatment options, according to a retrospective study led by LRF grantee Neha Mehta-Shah, MD of the Washington University School of Medicine in St. Louis.
As a follow-up from their 2017 study that showed 31 percent of patients remain disease-free three years after HCT, Shah and a group of researchers expanded their efforts to include more academic centers with longer follow-up.
The follow-up study included 508 patients with a median age of 51 years. More than 86 percent of patients had known remission status at the time of their allo-HSCT, with more than 54 percent obtaining a complete remission, 37 percent a partial remission, 23 percent stable disease and 3 percent progressive disease. Seventy-eight percent of patients received a prior autologous HCT.
After an allo-HSCT, the two- and five-year progression-free survival (PFS) rates were 45.8 percent and 39.4 percent, respectively; and the two-and five-year overall survival (OS) rates were 59.1 percent and 50.8 percent, respectively. The study showed no significant difference in PFS for patients with angioimmunoblastic T-cell lymphoma (AITL), peripheral T-cell lymphoma — not otherwise specified (PTCL-NOS), ALK-positive, or ALK-negative anaplastic large cell lymphoma (ALCL). However, when compared specifically, AITL trends towards improved media PFS and OS. At five years, PFS cutaneous T-cell lymphoma (CTCL) trends lower compared to PTCL subtypes, but overall survival was similar.
This study included contributions from LRF grantee and Scientific Advisory Board (SAB) member Steven Horwitz, MD of Memorial Sloan Kettering Cancer Center; LRF grantee Pamela Allen, MD, MSc of Winship Cancer Institute, Emory University; LRF grantee and LRF Mantle Cell Lymphoma Consortium (MCLC) member Jia Ruan, MD, PhD of Weill Cornell Medicine; LRF Mantle Cell Lymphoma (MCL) Consortium member and New York Lymphoma Rounds Steering Committee member Koen van Besien, MD, PhD of Weill Cornell Medicine; New England and New York Lymphoma Rounds Steering Committee member Francine Foss, MD of Yale Cancer Center; and Philadelphia Lymphoma Rounds Steering Committee member Stefan Barta, MD, MRCP, MS of Abramson Cancer Center, University of Pennsylvania.
More Updates from the 2020 American Society of Hematology Annual Meeting
Widely regarded as the premier event in malignant and non-malignant hematology, the virtual ASH Annual Meeting held from December 5-8, 2020 provided a critical forum for leading hematologists /oncologists to present their findings to over 20,000 of their peers.
Read More >